Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
23. Oktober 2024 07:00 ET
|
Olema Oncology
OP-3136, a potent KAT6 inhibitor, demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND submission...
Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients
17. Dezember 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage...
Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020
08. Dezember 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held...
Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology
03. Dezember 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology in support of Breast Cancer Index, the only commercially...
Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
29. Oktober 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast...
Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial
15. Mai 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
24. Februar 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
Breast Cancer Index® Receives Expanded Medicare Coverage Under a New Local Coverage Determination
05. März 2019 09:00 ET
|
Biotheranostics, Inc.
San Diego, CA, March 05, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces its Breast Cancer Index (BCI) test has been issued a new Medicare Local Coverage Determination [(LCD) L37822] by...
Younger Women Are More Likely to Be Non-Adherent to Oral Breast Cancer Therapies, Kantar Health Says
23. Mai 2016 16:06 ET
|
KantarHealth
NEW YORK CITY, N.Y., May 23, 2016 (GLOBE NEWSWIRE) -- Women who are younger, have lower income and are ethnically non-white are more likely to be non-adherent to oral endocrine therapy (ET) for breast...